Cancer Genetics, Inc. (CGIX) Expected to Post Earnings of -$0.13 Per Share
Analysts expect Cancer Genetics, Inc. (NASDAQ:CGIX) to report earnings per share of ($0.13) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Cancer Genetics’ earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.13). Cancer Genetics reported earnings of ($0.23) per share in the same quarter last year, which would indicate a positive year over year growth rate of 43.5%. The business is expected to announce its next earnings results on Thursday, November 9th.
According to Zacks, analysts expect that Cancer Genetics will report full year earnings of ($0.87) per share for the current financial year, with EPS estimates ranging from ($0.90) to ($0.83). For the next financial year, analysts forecast that the firm will report earnings of $0.03 per share, with EPS estimates ranging from ($0.05) to $0.10. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Cancer Genetics.
Cancer Genetics (NASDAQ:CGIX) last announced its quarterly earnings results on Monday, August 14th. The medical research company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). Cancer Genetics had a negative net margin of 68.48% and a negative return on equity of 48.78%. The company had revenue of $6.60 million for the quarter, compared to analysts’ expectations of $7.97 million. During the same quarter in the previous year, the business posted ($0.28) earnings per share. Cancer Genetics’s quarterly revenue was down 5.7% on a year-over-year basis.
CGIX has been the subject of a number of recent research reports. Benchmark Co. initiated coverage on Cancer Genetics in a research note on Monday, June 26th. They issued a “speculative buy” rating and a $6.00 target price for the company. Dawson James initiated coverage on Cancer Genetics in a research note on Tuesday, June 27th. They issued a “buy” rating for the company. Zacks Investment Research downgraded Cancer Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. HC Wainwright set a $6.00 target price on Cancer Genetics and gave the stock a “buy” rating in a research note on Tuesday, August 15th. Finally, ValuEngine downgraded Cancer Genetics from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. Cancer Genetics currently has an average rating of “Hold” and a consensus price target of $5.56.
In other Cancer Genetics news, Director John Pappajohn acquired 86,185 shares of the business’s stock in a transaction that occurred on Friday, August 18th. The stock was purchased at an average cost of $3.24 per share, with a total value of $279,239.40. Following the transaction, the director now owns 2,608,704 shares of the company’s stock, valued at $8,452,200.96. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have purchased a total of 272,370 shares of company stock valued at $933,479 over the last three months. Corporate insiders own 21.30% of the company’s stock.
Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Cancer Genetics by 61.9% during the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock worth $2,041,000 after purchasing an additional 197,619 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Cancer Genetics by 44.8% during the 1st quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock worth $1,843,000 after purchasing an additional 139,200 shares during the last quarter. EAM Investors LLC acquired a new stake in shares of Cancer Genetics during the 1st quarter worth about $483,000. Thompson Davis & CO. Inc. increased its position in shares of Cancer Genetics by 5,465.0% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock worth $440,000 after purchasing an additional 109,300 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Cancer Genetics by 61.0% during the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock worth $127,000 after purchasing an additional 12,168 shares during the last quarter. 16.08% of the stock is owned by hedge funds and other institutional investors.
Cancer Genetics (NASDAQ CGIX) traded down 3.03% on Friday, reaching $3.20. 60,124 shares of the company’s stock were exchanged. The firm’s market cap is $63.33 million. Cancer Genetics has a one year low of $1.10 and a one year high of $5.30. The firm has a 50 day moving average price of $3.52 and a 200 day moving average price of $3.58.
Cancer Genetics Company Profile
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cancer Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.